Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer

Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer

MD Anderson led Phase II study may lead to first systemic therapy for VHL disease HOUSTON ― In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with MK-6482, the small molecule inhibitor of […]